Portal de Periódicos da CAPES

Erythropoietin and Anemia of Gastrointestinal Bleeding in a Jehovah's Witness

1990; American College of Physicians; Volume: 112; Issue: 7 Linguagem: Inglês

10.7326/0003-4819-112-7-552_1

1539-3704

Lida Pousada, Joseph Fiorito, Carole Smyth,

Blood donation and transfusion practices

Letters and Corrections1 April 1990Erythropoietin and Anemia of Gastrointestinal Bleeding in a Jehovah's WitnessLida Pousada, MD, Joseph Fiorito, MD, Carole Smyth, RNC, NPLida Pousada, MDSearch for more papers by this author, Joseph Fiorito, MDSearch for more papers by this author, Carole Smyth, RNC, NPSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-112-7-552_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: The Federal Drug Administration recently approved marketing of epoetin alfa, a recombinant human erythropoietin, for treatment of anemia in patients with chronic renal failure (1, 2). Epoetin has also been shown to increase the ability of patients to donate autologous blood (3). We report the use of epoetin in a patient with an acute gastrointestinal bleed who, as a Jehovah's Witness, declined blood transfusion.A 66-year-old woman presented with two episodes of black stools during the previous week and a syncopal episode that day. Rectal examination showed heme-positive black stool. A spun hematocrit was 18%. The patient...References1. WinearlsOliverPippardReidDowningCotes CDMCMP. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic hemodialysis. Lancet. 1986;2:1175-8. CrossrefMedlineGoogle Scholar2. EschbachEgrieDowningBrowneAdamson JJMJJ. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-8. CrossrefMedlineGoogle Scholar3. GoodnoughRudnickPrice LST. Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med. 1989;321:1163-8. CrossrefMedlineGoogle Scholar4. Acts. 15:28.29. Google Scholar5. Gen. 9:3.4. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPostmortem serum erythropoietin levels in establishing the cause of death and survival time at medicolegal autopsyRecombinant Human Erythropoietin Therapy in Critically Ill Jehovah's WitnessesDoes recombinant human erythropoietin accelerate correction of post-ulcer-bleeding anaemia A pilot studyUse of Erythropoietin in the Severely Anemic Jehovah's Witness Patient: Case Report and Review of the LiteratureTraumatically Injured Jehovah's WitnessesThe use of erythropoietin in a patient having major oral and maxillofacial surgery and refusing blood transfusionUse of recombinant human erythropoietin to avoid blood transfusion in a Jehovah's Witness requiring hemispherectomyJehovah's witnesses and acute leukemiaUse of recombinant human erythropoietin in a Jehovah's WitnessLow-dose cytosine arabinoside as an alternative treatment for acute leukemia in Jehovah's Witnesses 1 April 1990Volume 112, Issue 7Page: 552-552KeywordsAnemiaBloodBlood transfusionDrug administrationErythropoietinHematocritHemorrhageRenal failureSyncope Issue Published: 1 April 1990 PDF DownloadLoading ...